Demographic Characteristics besides Clinical and Laboratory Manifestations of Children with Visceral Leishmaniasis in Rasht, Northern Iran
,
Abstract
Background: Visceral leishmaniasis (Kala-azar) is an inherently dangerous and progressive disease that can be seen in many parts of the world, including Iran. Therefore, we decided to conduct this study on children with Kala-azar in Rasht-Iran.
Methods: In this descriptive study, the hospital records of all children with Kala-azar disease admitted to 17 Shahrivar Hospital, Rasht- Iran from 2009 to 2021 were reviewed. Required information were collected from patients' records and descriptive statistical analysis was done using SPSS version 24 statistical software.
Results: A total of 22 children with visceral leishmaniasis were admitted to 17 Shahrivar Hospital during the study period. The average age of the children was 2.93 ± 3.32 years. Most of them (59.1%) were boys and lived in the foothills (59.1%). The most common season for children to get the disease was spring (45.5%), and the average duration of the disease until hospitalization was 16.5 ± 13.54 days. In this study, the most common clinical manifestations included fever (90.9%), splenomegaly (77.3%), hepatomegaly (50%), weakness and restlessness (27.3%), and vomiting (18.2%). The most common laboratory findings were anemia (90.9%), leukopenia (59.1%), increased erythrocyte sedimentation rate (ESR) (75%), and increased C-reactive protein (CRP) (75%). 72.7% of the children were treated with liposomal amphotericin and others with glucantime, which were all successful.
Conclusion: The results of our studies were consistent with most studies in Iran and other countries. These findings can help in the diagnosis and management of children with Kala-azar and better control of the disease in the province.
2. Shafiei R, Mohebali M, Akhoundi B, et al. Emergence of co-infection of visceral leishmaniasis in HIV-positive patients in northeast Iran: A preliminary study. Travel Med Infect Dis. 2014; 12 (2): 173- 8.
3. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012; 7(5): e35671.
4. Mohebali M. Visceral leishmaniasis in Iran: review of the epidemiological and clinical features. Iran J Parasitol. 2013; 8 (3): 348-58.
5. Mohebali M, Hajjaran H, Hamzavi Y, et al. Epidemiological aspects of canine visceral leishmaniosis in the Islamic Republic of Iran. Vet Parasitol. 2005; 129(3- 4): 243- 51.
6. Rassi Y, Abai MR, Oshaghi MA, et al. First detection of Leishmania infantum in Phlebotomus kandelakii using molecular methods in north-eastern Islamic Republic of Iran. East Mediterr Health J. 2012 ;18(4):387-92.
7. Topno RK, Das VNR, Ranjan A, et al. Asymptomatic infection with visceral leishmaniasis in a disease- endemic area in Bihar, India. Am J Trop Med Hyg. 2010; 83 (3): 502-6.
8. Biglino A, Bolla C, Concialdi E, Trisciuoglio A, Romano A, Ferroglio E. Asymptomatic Leishmania infantum infection in an area of northwestern Italy (Piedmont region) where such infections are traditionally nonendemic. J Clin Microbiol. 2010; 48 (1): 131- 6.
9. Rafeey M, Jodeiry B. Visceral leishmaniasis in children. Yafte. 2005; 6 (4) :35-41.
10. Kadivar MR. Childhood visceral leishmaniasis complicated by bacterial infections. East Mediterr Health J. 2000; 6 (5- 6), 879- 883.
11. Shamsian SA, Fata A, Alinezhad R,et al. Clinical and Laboratory Findings of Visceral Leishmaniasis in Children Hospitalized in Mashhad, Northeastern Iran: A Twenty-Year Retrospective Study. Iran J Parasitol. 2020;15(4):495-499.
12. Nourian M, Heidari A, Tajali S, Ghasemi E, Mohebali M, Heidari A. Paediatric visceral leishmaniasis: a retrospective study on clinical manifestations, demographic features and laboratory findings of hospitalized cases in Iran between 2006 and 2016. Trop Doct. 2019; 49(1):59-61.
13. Minodier P, Piarroux R, Garnier J- M, Unal D, Perrimond H, Dumon H. Pediatric visceral leishmaniasis in southern France. Pediatr Infect Dis J. 1998; 17 (8): 701- 4.
14. Totan M, Dagdemir A, Muslu A, Albayrak D. Visceral childhood leishmaniasis in Turkey. Acta Paediatr. 2002; 91 (1): 62- 4.
15. Maltezou HC, Siafas C, Mavrikou M, et al. Visceral leishmaniasis during childhood in southern Greece. Clin Infect Dis. 2000; 31 (5): 1139- 43.
16. Choobineh H, Mamishi S, Bahonar A, Safdari R, Rezaeian M, Vaez Zadeh F. Clinical And Epidemiological Aspects Of Kala-Azar In Hospitalized Cases In Childrens Medical Center (1988-2004). Iran J Pediatr, 2005; 15 (4): 327-32.
17. Altaf C, Ahmed P, Ashraf T, Anwar M, Ahmed I. Clinicopathological features of childhood visceral leishmaniasis in Azad Jammu & Kashmir Pakistan. J Ayub Med Coll Abbottabad. 2005; 17 (4):48-50.
18. Singh K, Singh R, Parija SC, Faridi MMA, Bhatta N. Clinical and laboratory study of kala- azar in children in Nepal. J Trop Pediatr. 1999; 45 (2): 95- 7.
19. Tamook A, Ashenaei F, Yegane Moghadam J, Chinifroosh M, Amini Sani N, Habibzadeh Sh. Clinical and laboratory characteristics of children with kalazar in Ardabil province. Ardabil Univ Med Sci. 2006; 7 (1): 27-34.
20. Minodier P, Garnier JM. La leishmaniose viscérale infantile en Provence [Childhood visceral leishmaniasis in Provence]. Arch Pediatr. 2000 ;7 Suppl 3:572s-577s. French.
21. Grech V, Mizzi J, Mangion M, Vella C. Visceral leishmaniasis in Malta- an 18 year paediatric, population based study. Arch Dis Child. 2000; 82 (5): 381- 5.
22. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BP, Nakamura CV. Recent advances in leishmaniasis treatment. Int J Infect Dis. 2011;15(8):e525-32.
23. Roatt BM, de Oliveira Cardoso JM, De Brito RCF,et al. Recent advances and new strategies on leishmaniasis treatment. Appl Microbiol Biotechnol. 2020;104(21):8965-8977.
| Files | ||
| Issue | Vol 18 No 2 (2023) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/ijpa.v18i2.13189 | |
| Keywords | ||
| Child Diagnosis Epidemiology Kala azar Visceral leishmaniasis Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
